Galvanize Therapeutics

What Galvanize Therapeutics does

Galvanize Therapeutics is a privately held biomedical platform company that develops and commercializes Pulsed Electric Field (PEF) energy-based medical devices for the surgical ablation of soft tissue, with a primary focus on oncology (lung tumors and other solid tumors) and chronic bronchitis/COPD. The company was formed in September 2022 through the merger of three electric pulse therapy companies incubated by Apple Tree Partners (ATP), and is headquartered in Redwood City, California, with approximately 101-250 employees.

The company's core proprietary Aliya PEF energy platform delivers short-duration, high-voltage electrical pulses to create electric fields that destabilize cell membranes, inducing non-thermal regulated cell death while preserving the extracellular matrix and sensitive surrounding structures. Commercialized products include the 510(k)-cleared Aliya PEF System, the next-generation Aliya EX Generator (cleared May 18, 2026, offering 2x the diameter and up to 7x the ablation volume of its predecessor), and the INUMI Flex Needle for endoscopic delivery. The RheOx Bronchial Rheoplasty System extends the same PEF modality bronchoscopically to treat chronic bronchitis symptoms, and is currently under FDA PMA Review in the United States. Clinical evidence includes 100% successful PEF ablation delivery and 96% local tumor control at 6 months in the AFFINITY trial (28 evaluable lung tumor patients), -9.0 CAT and -16.6 SGRQ score improvements at 12 months with RheOx, and a 2025 SIR Outstanding Laboratory Investigation Award for preclinical immune-stimulation research.

Galvanize generates revenue primarily through direct enterprise sales of medical device hardware and single-use disposable components (generators, needles, catheters) to US hospitals, thoracic surgeons, interventional pulmonologists, interventional radiologists, and oncologists. Pricing is quote-based and negotiated per hospital or healthcare system, with the Galvanize Patient Access Program bundling prior-authorization and reimbursement support to facilitate adoption. The company is not yet commercially active outside the United States. As of 2025-2026, Galvanize had raised approximately $248.5 million across multiple rounds, including a $100 million Series C led by Sofinnova Partners in September 2025.

Name

Galvanize Therapeutics

Legal name

Galvanize Therapeutics, Inc.

Website

https://galvanizetx.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

101–250 employees

Short description

Galvanize Therapeutics is a privately held biomedical platform company developing 510(k)-cleared Pulsed Electric Field medical devices — including the Aliya PEF System and Aliya EX Generator — for surgical ablation of solid tumors, with the RheOx system under FDA PMA Review for chronic bronchitis.

Ownership category

akta.pro rank

Product category

Pulsed Electric Field Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser) (HLAHADAC)

akta.pro secondary industry

Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC) (HLAHAGAD)

Keywords

• Pulsed electric field ablation
• Surgical soft tissue ablation
• Bronchial rheoplasty devices
• Medical device electrophysiology
• Interventional pulmonology equipment

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel

Revenue model

1. Hardware sales — Aliya PEF System (Generator, needles, catheters): Revenue from sale of the 510(k)-cleared Aliya EX Generator, Aliya PEF System, INUMI Flex Needle (percutaneous and endoscopic delivery), and the single-use RheOx catheter. These are medical device hardware sales to hospitals and healthcare systems.
2. Reimbursement support and patient access services: The Galvanize Patient Access Program provides proactive support to help practices manage prior authorization, coordinate appeals, submit documentation, and track cases through a secure provider portal. This is bundled with product sales to facilitate adoption.
3. RheOx Bronchial Rheoplasty System (investigational in US): RheOx is an investigational device in the United States limited by federal law to investigational use. Currently under PMA Review in the US; commercial clearance pending. International (European) registry study ongoing. Future revenue stream once PMA approval is obtained.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Galvanize Therapeutics develops and commercializes medical devices built on its proprietary Aliya Pulsed Electric Field (PEF) energy platform. The Aliya PEF System, Aliya EX Generator, and INUMI Flex Needle are 510(k) cleared for surgical ablation of soft tissue in the United States, while the RheOx System extends the same PEF modality to bronchoscopic treatment of chronic bronchitis and is currently under PMA review. The platform delivers short-duration, high-voltage electrical pulses to induce non-thermal regulated cell death while preserving the extracellular matrix.

Product overview

Galvanize Therapeutics operates as a biomedical platform company offering a single unified Pulsed Electric Field (PEF) technology architecture built around its proprietary Aliya platform. The commercialized Aliya family — the Aliya PEF System, the next-generation Aliya EX Generator, and the INUMI Flex Needle (all 510(k) cleared in the United States for surgical ablation of soft tissue) — enables non-thermal, regulated cell death for oncology and soft-tissue ablation applications, including the investigational AFFINITY and PROPEL clinical programs. The RheOx System extends the same Aliya PEF energy modality into a bronchoscopic product (Bronchial Rheoplasty) for chronic bronchitis (COPD) symptoms, currently under PMA review and limited to investigational use in the US. Together, the Aliya platform and its Aliya / INUMI / RheOx product instantiations form a single PEF energy platform applied across multiple disease targets.

Differentiator

Problem solved

Functional benefit

Brands

• Aliya: Galvanize's proprietary Pulsed Electric Field (PEF) energy platform and product system (Aliya PEF System, Aliya EX Generator, Aliya Needle, INUMI Flex Needle) for surgical ablation of soft tissue, including oncology indications such as lung tumors.
• RheOx

Products and services

• Aliya PEF System Capital equipment system that delivers high-voltage, short-duration Pulsed Electric Field energy to alter transmembrane potential and induce non-thermal regulated cell death for surgical ablation of soft tissue. 510(k) cleared in the United States for hospitals and surgical use.
• Aliya EX Generator Next-generation Pulsed Electric Field generator with flexible 1cm and 2cm ablation zones, percutaneous and endoscopic delivery options, foot latching, and adjustable audio/visual feedback. 510(k) cleared for surgical ablation of soft tissue.
• INUMI Flex Needle Minimally invasive endoscopic single-use delivery accessory for the Aliya PEF System that enables PEF energy to be delivered through a natural orifice (e.g., the mouth) to ablate soft tissue lesions while preserving non-target tissue and sensitive surrounding structures. 510(k) cleared in the United States.
• RheOx System (Bronchial Rheoplasty) Bronchoscopic system consisting of a proprietary electrosurgical generator and a single-use catheter that delivers short bursts of Pulsed Electric Field energy for non-thermal ablation of abnormal mucus-producing cells in the airways. Under PMA review in the United States for the treatment of chronic bronchitis symptoms; commercial pathway being developed in Europe.

Quantifiable outcome

• 100% successful PEF ablation delivery and 96% local tumor control across 28 evaluable patients with lung tumors at 6-month follow-up (AFFINITY trial)
• +5 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and flagship.

• AABIP (American Association for Bronchology and Interventional Pulmonology)coreGTM or Marketing PartnerGalvanize Therapeutics participates as an exhiber/attendee at the AABIP Annual Conference (August 20-22, 2026 in Denver, CO). The conference is a global platform for bronchology, interventional pulmonology, advanced diagnostic bronchoscopy, therapeutic bronchoscopy, pleural diseases, and thoracic surgery — Galvanize's primary clinical specialty audience.
• AATS International Thoracic Surgical Oncology Summit (ITSOS)coreGTM or Marketing PartnerGalvanize Therapeutics participates in the AATS ITSOS (September 26-27, 2025 in Boston, MA), which unites global thoracic surgical leaders for two days of cutting-edge scientific exchange in thoracic surgical oncology.
• CHEST (American College of Chest Physicians)coreGTM or Marketing PartnerGalvanize Therapeutics attends/exhibits at the CHEST Annual Meeting, a major conference for chest medicine specialists (pulmonologists).
• Merger partners (three electric pulse therapy companies)flagshipStrategic or Co-development PartnerIn September 2022, Galvanize Therapeutics announced a merger of three companies (including Gala Therapeutics and Galaxy Medical) to create a unified entity focused on pulsed electric field (PEF) therapy. The combined company concurrently completed a $100 million Series B financing. Galaxy Medical had separately received CE Mark for the CENTAURI PEF System (August 2022), and Gala Therapeutics had performed first commercial cases worldwide with the RheOx System for Chronic Bronchitis (February 2022).

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• AtriCure: Specializes in surgical ablation devices (including pulsed field/energy systems such as AtriFLEX) for cardiac arrhythmias — a directly comparable PEF energy surgical ablation platform with an FDA-cleared commercial footprint.
• AngioDynamics: Commercializes NanoKnife, the established irreversible electroporation (PEF) system for surgical ablation of soft tissue — the most direct competitive modality to Galvanize's Aliya platform in oncology.
• Pulmonx: Markets Zephyr Endobronchial Valves for emphysema/COPD, making it the closest direct peer in interventional pulmonology for chronic lung disease and a natural comparison point for Galvanize's RheOx in chronic bronchitis.
• Nuvaira: Develops targeted lung denervation (TLD) for COPD and chronic bronchitis — an interventional pulmonology competitor addressing overlapping patient populations with a different energy modality, directly comparable to RheOx.

Emerging players

• HistoSonics: Commercializes Edison histotripsy, a non-invasive, non-thermal mechanical ablation modality for soft tissue tumors — emerging competitor offering an alternative non-thermal ablation mechanism that could overlap with Aliya's positioning.
• INSIGHTEC: Commercializes focused ultrasound ablation platforms for non-invasive tissue ablation — emerging adjacent competitor demonstrating the broader shift toward non-thermal energy modalities in surgical oncology.

Broad incumbents

• Medtronic: Major incumbent in surgical ablation (radiofrequency, microwave, cryoablation) and broader interventional oncology — overlaps with Aliya in soft tissue ablation but across a much wider portfolio and global reach.
• Boston Scientific: Broad medtech incumbent with RF ablation and interventional pulmonary products (e.g., endobronchial therapies) — competes with Galvanize across both the Aliya oncology and RheOx respiratory franchises.
• Stryker: Diversified surgical and interventional device manufacturer including ablation and endoscopy-adjacent platforms — broad incumbent offering overlapping capabilities to Galvanize's energy-based surgical ablation portfolio.
• Johnson & Johnson (Ethicon / Biosense Webster): Operates leading surgical ablation (Ethicon) and pulsed field electrophysiology (Biosense Webster) franchises — broad incumbent with the most established PEF/surgical ablation portfolio that Galvanize competes against at scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/galvanize-therapeutics

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galvanize Therapeutics